» Articles » PMID: 20225664

Should We Routinely Measure Low-density and High-density Lipoprotein Subclasses?

Overview
Journal Clin Lab
Specialty Pathology
Date 2010 Mar 16
PMID 20225664
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) plasma populations are composed of heterogeneous subfractions that are different in size, density and protein/lipid content. There is increasing evidence that small, dense LDL particles are strongly associated with higher cardiovascular disease risk. Similarly, several studies have investigated whether smaller HDL particles are more protective than their larger counterparts and more recent findings suggest that small, dense HDL has significantly higher atheroprotective activity than larger HDL. Yet, certain impairments of the protein/lipid content in small, dense HDL may decrease its antiatherogenic capacity or even induce pro-atherogenic properties. Therefore, it seems that the small, dense phenomenon applies to both LDL and HDL particles. Measurement of LDL and HDL cholesterol concentrations has proven clinical utility, while the usefulness of LDL and HDL subclasses determination in clinical practice offers grounds for further exploration. However, LDL and HDL particles characterisation requires either special equipment or a lengthy analytical time and is, therefore, still unsuitable for general clinical use. It remains to be established whether lipoprotein subclasses should be analyzed in routine practice, although their assessment in high-risk subjects could be recommended.

Citing Articles

Effects of Longer-Term Mixed Nut Consumption on Lipoprotein Particle Concentrations in Older Adults with Overweight or Obesity.

Nijssen K, Chavez-Alfaro M, Joris P, Plat J, Mensink R Nutrients. 2025; 17(1.

PMID: 39796442 PMC: 11723242. DOI: 10.3390/nu17010008.


Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL.

Vekic J, Zeljkovic A, Stefanovic A, Bogavac-Stanojevic N, Ilias I, Silva-Nunes J Pharmaceutics. 2022; 14(4).

PMID: 35456658 PMC: 9027611. DOI: 10.3390/pharmaceutics14040825.


Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea.

Milojevic A, Zdravkovic M, Brajkovic M, Memon L, Gardijan V, Vekic J Med Princ Pract. 2022; 31(3):293-300.

PMID: 35292607 PMC: 9274940. DOI: 10.1159/000524087.


Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL.

Vekic J, Zeljkovic A, Cicero A, Janez A, Pantea Stoian A, Sonmez A Medicina (Kaunas). 2022; 58(2).

PMID: 35208622 PMC: 8877621. DOI: 10.3390/medicina58020299.


A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.

Vekic J, Zeljkovic A, Al Rasadi K, Cesur M, Silva-Nunes J, Pantea Stoian A Metabolites. 2022; 12(2).

PMID: 35208183 PMC: 8879153. DOI: 10.3390/metabo12020108.